Preclinical studies and early-phase clinical trials have demonstrated that BTLA agonists can reduce airway inflammation, improve lung function, and decrease T cell numbers in animal models of asthma, with initial human studies suggesting beneficial effects on controlling inflammation and improving asthma symptoms (21, 39, 77). This evidence concerns the gene BTLA and asthma.